AllDocs -> cancers

676 Annals Academy of Medicine Ovarian Cancer Screening—N D MacDonald et al Screening for Ovarian Cancer N D MacDonald,* MBBS (Hons) , A N Rosenthal,* BSc (Hons), MBBS , I J Jacobs,** MD, MRCOG Abstract Ovarian cancer is predominantly a disease of postmenopausal women which presents at a late stage and has an overall 5-year survival of less than 30%. If detected at stage I, survival is dramatically increased and this would suggest that screening for ovarian cancer may reduce mortality. However, the inaccessibility of the ovaries and the absence of a confirmed premalignant condition make screening for preclinical disease difficult. Recent advances in tumour marker interpretation and ultrasound technology have now allowed screening for ovarian cancer to become a real possibility. CA 125 is the most ...

Abstract. Antizyme is a negative regulator of cellular poly- amines. The gene for antizyme ( OAZ1 ) is mapped to 19p13.3, where frequent allelic imbalance (AI) is observed in ovarian cancer . The potential role of antizyme 1 in ovarian carcino- genesis was addressed in this study. Mutations of the OAZ1 gene, including the entire coding region and associated promoter region, were examined in 50 primary ovarian tumors and 8 ovarian cancer cell lines by PCR-SSCP and sequencing analyses. A missense mutation in exon 1 and a nucleotide change at the 3'-UTR were detected in an ovarian cancer cell line and its derivative cisplatin resistant cell line. No somatic mutation was detected in primary ovarian tumors, although 7 polymorphic sites were identified. AI of the OAZ1 gene was detected in 7 of 30 informative cases of primary ovarian cancer (23%). Subsequent ...

continued on back Ovarian cancer is the rapid growth of abnormal cells in the ovaries of the female reproductive system. The ovaries are the two small egg-filled sacs on each side of the uterus which produce estrogen and play a key role in conception and menstruation. Cancer can occur in one or both ovaries. When there is a malignancy, the ovaries typically enlarge, and cancer cells may fall off the ovary’s surface and implant themselves throughout the abdominal cavity. Each one of these seedlings can then grow into a separate ovarian cancer tumor nodule. Who is at risk for ovarian cancer ? Each year, more than 20,000 American women will be diagnosed with ovarian cancer . The disease most often affects post- menopausal women, although women of any age may develop it. While scientists have not uncovered the cause, women ...

OVARIAN CANCER NATIONAL ALLIANCE’S SIXTH ANNUAL ADVOCACY CONFERENCE September 17-19, 2003 San Francisco, CA Scholarship Application NAME: __ ORGANIZATION/AFFILIATION: __ HOME ADDRESS: _ HOME PHONE: __ WORK PHONE: EMAIL: __ Please answer the following questions (type or print in ink). The application must be received at the Alliance office by August 1 , 2003 and you will be notified by August 15, 2002 . Priority will be given to survivors with financial need who have not previously received financial assistance and who are working with an Alliance Partner Member group or community-based ovarian cancer advocacy group to implement ideas from the conference. 1. How do you plan to use the information you obtain from the conference to increase attention to ovarian cancer issues in your community? 2. Describe your current ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com * Findings were statistically significant (strong evidence) + Evidence of a dose-response relationship (strongest evidence) Page 80 Ovarian Cancer and Exposure to Ionizing Radiation Summary : There has been moderately strong evidence recorded of a possible connection between ovarian cancer and exposure to ionizing radiation. This possible connection is supported by evidence from studies conducted at Los Alamos National Laboratory and other studies of nuclear workers at other sites who have been exposed to ionizing radiation. The National Research Council’s has determined that there is evidence among atomic bomb survivors of ovarian cancer in connection with exposure to ionizing radiation. Ovarian ...

1 IMAGING OVARIAN CANCER Hedvig Hricak, M.D., Ph.D. INTRODUCTION Imaging has become an important adjunct to the clinical assessment of a patient with gynecologic cancer , contributing to tumor detection, character- ization, staging, treatment planning and follow-up. Imaging, integrated into clinical findings, can optimize patient care and assist in developing a patient specific disease management plan. Over the last two decades, advances in cross-sectional imaging, including ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), and Positron Emission Tomography (PET) have yielded new insights into the evaluation of morphologic and functional tumor prognostic factors. Although advances in diagnostic imaging have been described, they have not been widely disseminated and in- corporated into routine gynecologic oncology practice. With emphasis on education ...

CODE: PACLICARBO CCO Formulary January, 2003 A REGIMEN NAME PACLITAXEL-CARBOPLATIN (PACLICARBO) Chemotherapy Cancer Ovarian Cancer (Stage II, III, or IV, optimally debulked) Primary Peritoneal Cancer Fallopian Tube Cancer Curative RESTRICTED CCO: a regimen which requires eligibility confirmation for reimbursement by the CCO New Drug Funding Program Indications and Rationales First line postoperative chemotherapy regimen for newly diagnosed stage II-IV epithelial ovarian cancer . B DRUG REGIMEN PACLITAXEL ( Round to nearest 3 mg) 175/m 2 IV (give first) Day 1 Give Paclitaxel before Carboplatin CARBOPLATIN (Round to nearest 5mg) AUC 5-7.5 IV Day 1 Adjust Carboplatin dose to AUC target ...

D ATA S HEET Rev 050300A CA125 ( Ovarian Cancer Antigen) Ab-1 (Clone Ov185:1) Mouse Monoclonal Antibody Cat. #MS-1151-S0, -S1, or -S (0.1ml, 0.5ml, or 1.0ml Supernatant) Cat. #MS-1151-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining) Cat. #MS-1151-PCS (5 Slides) (Positive Control for Histology) ! "#$! %& # #"! !$ ' % %() * %() + ( , ,, %( ) + Specificity and Comments: Recognizes a protein, identified as CA125 ( Ovarian Cancer Antigen). CA125 is a tumour marker usually associated with ovarian epithelial malignancies. Serum assays are widely used to detect this protein in ...

ovarian cancer Screening for ovarian ca ? BMJ editorial 99 ? Urban We now need a definitive randomised trial Computer simulation models predict that ovarian cancer screening could save at least three years of life per case and that screening is potentially cost effective. Jacobs et al (Lancet 99) recently described a randomised controlled trial of ovarian cancer screening in which 21 935 average risk postmenopausal women were randomised to three annual screens or to a control group. For their screening protocol Jacobs et al used the CA125 tumour marker as a first line screen and referred women to receive transvaginal sonography if CA125 concentrations were above 30 U/ml. If transvaginal sonography revealed an ovarian mass, women were referred for surgery. Designed as a pilot study, the trial was too small to show efficacy in terms ...

8 (NAPSA)—Given how busy the holiday season can be, it’s a good idea to save time wherever you can. One way to do so is with delicious, decorative desserts that can be pre- pared ahead of time, put together in minutes and brought out as delectable endings to celebratory gatherings. These easy-to-make ice cream recipes from Blue Bunny are sure to be a memorable addition to any family’s holiday feast. Jamaican Pumpkin Pie is an unusual twist on the Thanksgiv- ing classic, while Snowman is not just a dessert—it’s also an edible holiday decoration. JAMAICAN PUMPKIN PIE Crust: 1 1 / 4 cups gingersnap cookie crumbs (about 25 cookies) 2 tablespoons sugar 3 tablespoons butter, melted Filling: 1 / 4 to 1 / 2 ...

Facts Ovarian cancer is the second most common gynecologic cancer in the United States. It is estimated that more than 23,000 women will be diagnosed with ovarian cancer in 2002. with Maurie Markman, MD of the Cleveland Clinic Monday, September 23 rd from 4 – 5 PM ET People Living With Cancer website (www.plwc.org) Pre-registration for the chat begins September 17 th . In observance of Ovarian Cancer Awareness Month, the American Society of Clinical Oncology (ASCO) invites you to visit the new website, People Living With Cancer (www.plwc.org) and take part in a live question and answer chat with Maurie Markman, MD. During this one-hour session, Dr. Markman will answer your questions on topics such as new treatments, early detection and how genetics may play a role in ...

Abstract . Standard therapy for patients affected with advanced epithelial ovarian cancer is cytoreductive surgery followed by combination chemotherapy. With this treatment, most patients obtain clinical complete or partial response, nevertheless, relapse is common and salvage chemotherapy is often needed. The probability of response to second line chemotherapy following platinum-based treatments is usually related to the platinum-free interval, even if recent studies have reported some other clinical features as having prognostic value, such as tumour burden and histology. Salvage monochemotherapy is generally used, but when the platinum-free interval is longer than 24 months, re-treatment with platinum compounds and/or taxanes is indicated. Moreover, a number of new agents with demonstrated activity in ovarian cancer are currently available. Sequentially used in recurrent disease, ...

For Internal Use Only. Not For Use With The Public. This material is intended for insurance informational purposes only and is not personal medical advice for clients. Prudential Financial is a service mark of The Prudential Insurance Company of America, Newark, NJ and its affiliates The Prudential Insurance Company of America 751 Broad Street, Newark, NJ 07102-3777 RX53 DOC IFS-A013024, Ed. 05/02, Exp. 11/03 Ovarian Cancer Ovarian cancer accounts for 5% of all cancers in women and is most common in the 40-70 year age group. The incidence is increasing in highly industrialized countries and it is more common in women of higher socioeconomic status. The latter may be due to the smaller number of pregnancies in that group. Women who have not borne children are at an increased risk of ovarian cancer . Other risk factors include: early menopause, high fat diet, positive family ...

The Breast and Ovarian Cancer Genetics Program Supplemental Questionnaire Patient Name: MRN What is the highest level of schooling you completed? Grade School High School College Graduate School Were you ever, or are you currently married? No Yes--> How old were you when you first married? PREGNANCY HISTORY Have you ever had a twin or triplet pregnancy? No Yes Have you ever had a miscarriage or stillbirth: No Yes ---> If yes, number of miscarriages or stillbirths? BIRTH CONTROL PILL USE At what age did you first use the pill? __ Did you use the pill during your thirties No Yes ---> If yes, how many months did you use the pill during your thirties? All totaled, about how many months did you use the pill?__ At what age did you last use the birth control pill (current age if still using)? IF YOU HAD ...

Pacific Ovarian Cancer Research Consortium (POCRC) Advocate Quarterly Meeting Saturday, September 29, 2001 9:00 AM - 1:00 PM Minutes Introductions: Sheryl Eisenbarth, POCRC Patient Advocacy Coordinator, started the meeting by inviting each advocate to introduce herself and share why they were part of the POCRC advocate group. It was decided that each meeting will begin with an “Advocate in Action” story. Ovarian Cancer National Alliance (OCNA) Advocacy Conference: Shirley Inveen shared her experience at the OCNA Conference “ Ovarian Cancer : Silent No More” held 9/19-22, 2001 in Indianapolis, IN. Shirley had to leave her Gig Harbor home at 3:00 AM in the morning to catch her flight and represent us at the conference! Free webcasts of the conference can be viewed at www.cancereducation.com . Sessions included cancer genetics, new and promising treatment therapies, prolonging ...

ovarian cancer THE UK OVARIAN SCREENING PROGRAM When ovarian cancer is detected early, women can be cured with existing treatment methods. Early detection is the main focus of the Ovarian Cancer Screening Program at the University of Kentucky. The Kentucky Extension Homemakers are looking for support from the business community for this important program, which is offered free to Kentucky women. Facts About UK Ovarian Screening: Started by a Kentucky Homemaker with ovarian cancer . Goal: reduce ovarian cancer mortality in the group screened. Over 15 years of contributions from KEHA members. Uses transvaginal ultrasound (TVS) for detection. TVS detects virtually all small ovarian cancers. Has delivered free screening to women for over 10 years. ~14,000 participants have received ~60,000 TVS screens. ...

ovarian cancer Ovarian Cancer : the Place of Conservative Surgery P. Schwartz Yale University School of Medicine, New Haven, CT, USA Introduction Ovarian cancer is the second most common site for cancer to develop in the female pelvic reproductive organs in the United States , but it is the most deadly of the common pelvic reproductive organ cancers. The mainstay for the management of the common epithelial ovarian cancer is aggressive cytoreductive surgery followed by intense combination chemotherapy. However, aggressive surgery is inappropriate for the less common ovarian germ cell malignancies which represent approximately 5% of all ovarian cancers and early stage sex cord-stromal malignancies which are even less frequent. Additionally, selected cases of young women with common epithelial ovarian cancers in an early stage may be spared aggressive cytoreductive surgery in ...

PREDISPOSING GENES IN HEREDITARY BREAST AND OVARIAN CANCER P I A H U U S K O Department of Clinical Genetics OULU 1999 Page 2 O U L U N Y L I O P I S T O , O U L U 1 9 9 9 PREDISPOSING GENES IN HEREDITARY BREAST AND OVARIAN CANCER PIA HUUSKO Academic Dissertation to be presented with the assent of the Faculty of Medicine, University of Oulu, for public discussion in Auditorium 9 of the University Hospital of Oulu, on September 11th, 1999, at 12 noon. Page 3 Copyright © 1999 Oulu University Library, 1999 OULU UNIVERSITY LIBRARY OULU 1999 ALSO AVAILABLE IN PRINTED FORMAT Manuscript received 16 August 1999 Accepted 18 August 1999 Communicated by Docent Lauri Aaltonen Professor Heikki Joensuu ISBN 951-42-5442-2 ...

ovarian cancer Familial Breast and Ovarian Cancer : Genetic Counseling and Clinical Management in Italy. Barbara Pasini and Marco A. Pierotti Hereditary Tumors Unit, Istituto Nazionale Tumori - Milan (pasini@istitutotumori.mi.it) In Italy, where the health system is mainly public (although an increasing number of private clinics is coming up), genetic counseling on inherited predisposition to cancer and related genetic tests are generally offered on the basis of finalized research projects lacking of specific national guide lines. Genetic counseling services on familial breast and ovarian cancer have been already established in Milan, Modena, Naples, Varese, and Genoa while their organization is in progress in Aviano, Chieti, Florence, Padova, Pisa, Rome and Turin. Counseling is usually offered as an outpatient service in the context of medical genetics services, departments of oncology, ...

ovarian cancer CLINICAL SERVICES FOR FAMILIAL BREAST AND OVARIAN CANCER IN GERMANY MW Beckmann Department of Obstetrics&Gynecology, Heinrich-Heine-Universita~t, Du~sseldorf, Germany Multiple hereditary cancer sydromes have been defined including the hereditary nonpolyposis colon cancer (HNPCC) and the familial breast and ovarian cancer (HBOC) syndromes. Germ line mutations of the cancer susceptibility genes BRCAI and BRC~ seem to be a major part of the HBOC syndrome. Gynecological cancers like breast, ovarian and endometrial cancer are the most abundant cancer types. Public awareness and interest about predictive genetic testing for 'late onset' diseases are large due to scientific efforts (human genome project) and permanent publicity in the mass media. Personal expectations are focussed towards the specific cancer sydrome asking for detailed information about risk ...

Density and CD11b expression of eosinophils from ovarian cancer patients receiving recombinant human interleukin-3 after chemotherapy C. Berends, G.J. Veldhuis*, B. Dijkhuizen, P.H.B. Willemse*, E.G.E. de Vries* and H.F. Kauffman Divisions of Allergology and Medical Oncology * , Department of Internal Medicine, University Hospital Groningen, Groningen, The Netherlands. Submitted 37 Chapter 2 Page 2 38 Chapter 2 Abstract Several studies have shown that interleukin-3 (IL-3) enhances eosinophil activity in vitro. The in vivo effects of IL-3 on circulating human eosinophils, however, may be modulated by the presence of other cell-types and cytokines. Activation of eosinophils during recombinant human IL-3 (rhIL-3) administration is likely to occur since allergy- like side effects have been reported ...

Ovarian Cancer Coalition of Greater California 6 th Annual Run/Walk – September 12, 2004 Pledge Form* * Pledges are NOT required for participation. But every dollar helps us fund research for an early detection test. Please bring your completed pledge forms with donations to the registration area the morning of the Run/Walk. Photocopies are accepted. Your cancelled check is your receipt. Run/Walk Participant Name: Address: City: State: Zip: Day Phone: Donors 1. Name: Total $ Address: 2. Name: Total $ Address: 3. Name: Total $ Address: 4. Name: Total $ Address: 5. Name: Total $ Address: 6. Name: Total $ Address: Total Pledges $_ Total Collected $__ ...

1 OVARIAN CANCER Tally Levy, MD Division of Gynecologic Oncology Dept of Obstetrics and Gynecology Wolfson Medical Center – Holon - Israel Statistics • 5% of all cancers among women • 23% of gynecological cancers • 4 th cause for cancer death in women • 47% of all deaths from gynecological cancers • One out of 56 women will develop ovarian cancer in her life-time • In the US each 45 min a woman dies from ovarian cancer Statistics • Percent probability at birth of ever developing cancer (females, US 1995): All sites 1/3 Breast 1/8 Cervix 1/91 Corpus 1/45 Lung 1/19 Ovary 1/56 Colon-rectum 1/17 Page 2 2 Classification • Neoplasms derived from the coelomic epithelium • Neoplasms ...

Inhibition of human ovarian and breast cancer cell growth by telomere - specific DNA Lee Hng Wee under the direction of Dr. Mark Eller Department of Dermatolology Boston University School of Medicine Research Science Institute August 1, 2002 Page 2 Abstract The 11mer oligonucleotide homologous to the telomere 3’ single stranded overhang, which we named T-oligo, deserves attention as a selective target for cancer therapy because of its immense potential to inhibit cancer cell growth. Using well-characterized model systems for ovarian and breast cancer , we define here the cellular consequences of T-oligo treatment in these cells through studying its ability to inhibit ovarian and breast cancer cell growth, and the pathway by which it does so. We discovered that the T-oligo induces features of replicative senescence in both cancer ...

Donna Karan, Charla Lawhon and invite you to S u p e rS a t u r d ay 6 to benefit THE OVARIAN CANCER RESEARCH FUND SATURDAY, JULY 26, 2003, 1 P.M. - 6 P.M. (EXCLUSIVE PREVIEW SHOPPING NOON - 1 P.M.) AT NOVA’S ARK PROJECT, 60 MILLSTONE ROAD, WATER MILL, NY SHOP TILL YOU DROP at our world famous designer garage sale and enjoy the super kids’ carnival with rides and games galore, In Style photo booths, and arts & crafts. Plus, don’t miss the stellar raffle, delicious lunch, snacks and refreshments, live entertainment, and many more fun surprises! Grand Benefactor: Betty Crocker Kids’ carnival sponsor: Toys “R” Us Benefactors: The Group for Women, The Sandler Family Patron: Hamptons Magazine Benefit Committee CHAIRS: Patti and Harvey Cohen & Faith and Jeffrey Kogan; Fabien Baron and Malin Ericson, Loraine and Peter ...

P.O. Box 12504 - Arlington, Virginia 22219 Phone: (703) 346-3893 www.ovariancancercoalition.org Fax: (703) 476-1976 OGCC is a non-profit 501(c)(3) organization and contributions are tax deductible to the fullest extent allowed by law. OGCC’s tax id number is 54-2004729. A Partner of the Ovarian Cancer National Alliance/Ovar’coming Together The Ovarian & Gynecologic Cancer Coalition Of Greater Washington – “Rhonda’s Club” Schedule of Events May & June 2004 Monday, May 10, 2004, 6:30 to 8:30 p.m. Serum Proteomics and the Hottest News Direct from the Society of Gynecologic Oncologists (SGO) Featuring Dr. James Barter Fresh from the annual SGO meeting, Dr Barter will present serum proteomics and forecast how this will change clinical practice and our diagnostic and monitoring experiences. He will discuss ...

Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo Antonia E. Stephen* † , Peter T. Masiakos*, Dorry L. Segev*, Joseph P. Vacanti † , Patricia K. Donahoe*, and David T. MacLaughlin* ‡ *Pediatric Surgical Research Laboratories, and † Laboratory for Tissue Engineering and Organ Fabrication, Department of Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114 Contributed by Patricia K. Donahoe, December 28, 2000 Techniques of tissue engineering and cell and molecular biology were used to create a biodegradable scaffold for transfected cells to produce complex proteins. Mullerian Inhibiting Substance (MIS) causes regression of Mullerian ducts in the mammalian embryo. MIS also causes regression in vitro of ovarian tumor cell lines and ...